Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beximco PharmaceuticalsBXMPY 94 EV-to-EBIT is 9.83 as of Aug. 08, 2026, which is 8% below its 10-year median of 10.64. GuruFocus rates BXMPY with a GF Score™ of 94/100. The stock has 5 warning signs investors should review. Among 686 Drug Manufacturers companies, Beximco Pharmaceuticals ranks better than 86.44% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Beximco Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2026 was $0.00 Mil.
Beximco Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $96.93 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beximco Pharmaceuticals EV-to-EBIT Related Terms
Beximco Pharmaceuticals EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beximco Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Beximco Pharmaceuticals's EV-to-EBIT falls into.
Beximco Pharmaceuticals's current Enterprise Value is $952.81 Mil.
Beximco Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $96.93 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beximco Pharmaceuticals (BXMPY) has a EV-to-EBIT of 9.83 as of Aug. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Beximco Pharmaceuticals and its competitors. This is near median its historical median of 10.64. Over the past decade, Beximco Pharmaceuticals' EV-to-EBIT has ranged from 3.81 to 19.59. According to the industry distribution chart, Beximco Pharmaceuticals ranks #93 out of 686 companies in the Drug Manufacturers industry, placing it in the top 13.6%.
Is Beximco Pharmaceuticals' EV-to-EBIT too high?
Beximco Pharmaceuticals' current EV-to-EBIT of 9.83 is near median its 10-year median of 10.64. Over the past 10 years, this metric has ranged from a low of 3.81 to a high of 19.59. The Drug Manufacturers industry median EV-to-EBIT is 15.73. Beximco Pharmaceuticals' value of 9.83 is 37.5% below this industry median. Based on the distribution chart, Beximco Pharmaceuticals ranks #93 out of 686 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Beximco Pharmaceuticals has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Beximco Pharmaceuticals ranks #93 out of 686 companies for EV-to-EBIT. This places Beximco Pharmaceuticals in the top 14% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.73. Beximco Pharmaceuticals' value of 9.83 is 37.5% below this benchmark. Historically, Beximco Pharmaceuticals' own EV-to-EBIT has ranged from 3.81 to 19.59 over the past decade. While the company's 10-year median is 10.64 vs. the industry median of 15.73, Beximco Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.73, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beximco Pharmaceuticals's current EV-to-EBIT of 9.83 is 37.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Beximco Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beximco Pharmaceuticals's current EV-to-EBIT is 9.83, which is near median its own 10-year median of 10.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Beximco Pharmaceuticals (BXMPY) has a current EV-to-EBIT of 9.83. The current EV-to-EBIT is 9.83, which is near median its 10-year median of 10.64 and 37.5% below the Drug Manufacturers industry median of 15.73. Beximco Pharmaceuticals' overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Beximco Pharmaceuticals (BXMPY), the current EV-to-EBIT is 9.83 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BXMPY has been successfully added to your 
